Publication:
An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

dc.contributor.authorYUMUK, PERRAN FULDEN
dc.contributor.authorsCicin, İrfan; Oukkal, Mohammed; Mahfouf, Hassen; Mezlini, Amel; Larbaoui, Blaha; Ahmed, Slim Ben; Errihani, Hassan; Alsaleh, Khalid; Belbaraka, Rhizlane; Yumuk, Perran Fulden; Goktas, Burce; Özgüroğlu, Mustafa
dc.date.accessioned2022-03-23T14:15:23Z
dc.date.accessioned2026-01-11T08:37:20Z
dc.date.available2022-03-23T14:15:23Z
dc.date.issued2022-12-30
dc.identifier.doi10.4274/ejbh.galenos.2021.2021-9-9
dc.identifier.issn2587-0831
dc.identifier.pubmedPMID: 35059593 PMCID: PMC8734518
dc.identifier.urihttps://hdl.handle.net/11424/254747
dc.language.isoeng
dc.relation.ispartofEuropean Journal of Breast Health
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectbreast cancer
dc.subjectHER2
dc.subjectpatient satisfaction
dc.subjectsubcutaneous
dc.subjecttrastuzumab
dc.titleAn Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage73
oaire.citation.startPage63
oaire.citation.titleEuropean Journal of Breast Health
oaire.citation.volume1

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
602.47 KB
Format:
Adobe Portable Document Format